- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02856893
Osimertinib Treatment on EGFR T790M Plasma Positive NSCLC Patients (APPLE) (APPLE)
APPLE Trial: Feasibility and Activity of AZD9291 (Osimertinib) Treatment on Positive PLasma T790M in EGFR Mutant NSCLC Patients
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Primary objective To evaluate the best strategy for delivering Osimertinib (AZD9291) in NSCLC patients with EGFR mutation. The objective is assessed by Progression Free Survival rate at 18 months (PFS-18).
Secondary objectives
- To evaluate PFS on Osimertinib measured from randomization by RECIST criteria 1.1 [Ref 33].
- To evaluate PFS measured from switching to Osimertinib by RECIST criteria 1.1 [Ref 33].
- To determine the proportion of patients receiving Osimertinib based on the determination of cfDNA T790M mutation positive.
- To evaluate time to symptomatic brain metastases in patients with presence of brain metastases at study entry.
- To evaluate PFS-2 (defined as the sum of the PFS to Gefitinib and the PFS to Osimertinib treatment).
- To evaluate Overall Response Rate (ORR) to Osimertinib.
- To evaluate the Treatment duration.
- To evaluate Time to progression (TTP) on Osimertinib (measured from switching to osimertinib).
- To evaluate Overall Survival (OS).
- To evaluate time to brain progression (TTBP).
- Safety.
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Bordeaux, France
- Institut Bergonié
-
Brest, France
- CHU de Brest
-
Caen, France
- Centre François Baclesse
-
Créteil, France
- Centre Hopitalier Intercommunal De Creteil
-
Marseille, France
- Institut Paoli-Calmettes
-
Marseille, France
- Assistance Publique - Hopitaux de Marseille - Hopital Nord
-
Strasbourg, France
- Centre Paul Strauss
-
Toulouse, France
- CHU Toulouse - Hopital Larrey
-
Vandœuvre-lès-Nancy, France
- Institut de Cancérologie de Lorraine
-
Villejuif, France
- Gustave Roussy
-
-
-
-
-
Amman, Jordan
- King Hussein Cancer Center
-
-
-
-
-
Gdansk, Poland
- Medical University of Gdansk
-
-
-
-
-
Golnik, Slovenia
- University Clinic Golnik
-
Ljubljana, Slovenia
- The Institute Of Oncology
-
-
-
-
-
Barcelona, Spain
- Hospital de la Santa Creu i Sant Pau
-
Barcelona, Spain
- Vall d'Hebron Institut d'Oncologia
-
Barcelona, Spain
- Hospital Clinic Universitari de Barcelona
-
Coruna, Spain
- University Hospital A Coruna-Hospital Teresa Herrera
-
Madrid, Spain
- Hospital Universitario 12 de Octubre
-
Madrid, Spain
- Hospital Universitario Ramon Y Cajal
-
Mataró, Spain
- Institut Catala d'Oncologia - ICO Badalona - Hospital De Mataro
-
Sevilla, Spain
- Virgen del Rocio University Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion:
Registration:
- Pathological diagnosis of adenocarcinoma of the lung carrying common EGFR activating mutations associated with EGFR-TKI sensitivity (Del19 or L858R); performed locally; no other EGFR mutations will be allowed. In case of other (than EGFR) concomitant mutations, discussion with EORTC Headquarters is mandatory;
- Stage IV NSCLC;
- Blood sample available for cfDNA EGFR T790M central testing;
- Age ≥18 years;
- EGFR TKI treatment-naïve eligible to receive first-line treatment with EGFR TKI;
- Prior adjuvant and neo-adjuvant therapy is permitted (chemotherapy, radiotherapy, investigational agents) if performed more than 12 months before registration;
- Before patient registration/randomization, written informed consent must be given according to ICH/GCP, and national/local regulations
Randomization:
- Report of adequacy sample for cfDNA EGFR T790M test by central laboratory;
- Prior palliative radiotherapy or surgery are allowed if completed at least 4 weeks before the randomization;
- Patients with brain metastases are allowed provided they are stable (i.e. without evidence of progression by imaging for at least two weeks prior to the first dose of trial treatment and without deterioration of any neurologic symptoms), and have not received steroids for at least 7 days before randomization; Baseline tumor assessment scans are done within 21 days before randomization;
- Evaluable disease as defined below;
- At least one lesion, not previously irradiated and not chosen for biopsy during the study screening period, that can be accurately measured at baseline as ≥10 mm in the longest diameter (except lymph nodes which must have a short axis of ≥15 mm) with computed tomography (CT) or magnetic resonance imaging (MRI), and which is suitable for accurate repeated measurements.
- WHO Performance Status 0-2, with no clinically significant deterioration over the previous 2 weeks and a minimum life expectancy of 12 weeks;
- Adequate bone marrow, renal, hepatic and liver function within 21 days from randomization and defined as follows:
- Absolute neutrophil count ≥1.5 x 109/L;
- Platelet count ≥100 x 109/L;
- Haemoglobin ≥9 g/dL;
- Alanine aminotransferase (ALT) ≤2.5x the upper limit of normal (ULN) if no demonstrable liver metastases or ≤5xULN in the presence of liver metastases;
- Aspartate aminotransferase (AST) ≤2.5xULN if no demonstrable liver metastases or ≤5xULN in the presence of liver metastases;
- Total bilirubin ≤1.5xULN if no liver metastases or ≤3xULN in the presence of documented Gilbert's Syndrome (unconjugated hyperbilirubinaemia) or liver metastases;
- Serum creatinine ≤1.5xULN concurrent with creatinine clearance ≥50 mL/min (measured or calculated by Cockcroft and Gault equation);
- No significant comorbidity that according to the investigator would hamper the participation on the trial;
- Female patients should be using adequate contraceptive measures, should not be breastfeeding, until 12 months after the last dose, and must have a negative pregnancy test (serum or urine) prior to first dose of study drug (within 72 hours); or female patients must have an evidence of non-child-bearing potential by fulfilling one of the following criteria at screening:
- Post-menopausal defined as aged more than 50 years and amenorrheic for at least 12 months following cessation of all exogenous hormonal treatments.
- Women under 50 years old would be consider postmenopausal if they have been amenorrheic for 12 months or more following cessation of exogenous hormonal treatments and with luteinizing hormone (LH) and follicle-stimulating hormone (FSH) levels in the post-menopausal range for the institution.
- Documentation of irreversible surgical sterilisation by hysterectomy, bilateraloophorectomy, or bilateral salpingectomy but not tubal ligation.
Male patients should be willing to use barrier contraception, i.e., condoms
o Male patients will be advised to arrange for the freezing of sperm samples prior to the start of the study should they wish to father children, and not to donate sperm until 6 months after discontinuation of study treatment." (as per Investigator Brochure, IB)
- Absence of any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the patient before registration in the trial.
Exclusion:
- Treatment with any of the following:
- Prior treatment with any systemic anti-cancer therapy for locally advanced/metastatic NSCLC including chemotherapy, biologic therapy, immunotherapy, or any investigational drug;
- Prior treatment with an EGFR-TKI;
- Major surgery (excluding placement of vascular access) within 4 weeks before randomization;
- Radiotherapy treatment to more than 30% of the bone marrow or with a wide field of radiation within 4 weeks before randomization
- Patients currently receiving (or unable to stop use at least 1 week prior to receiving the first dose of study drug) medications or herbal supplements known to be potent inhibitors or inducers of cytochrome P450 (CYP) 3A4;
- Other anti-cancer therapies and alternative medications such as homeopathic treatment, etc;
- Treatment with an investigational drug within five half-lives of the compound or any of its related material, if known;
- Leptomeningeal carcinomatosis; spinal cord compression;
- Any unresolved toxicities from prior systemic therapy (e.g., adjuvant chemotherapy) greater than CTCAE grade 2 at the time of randomization;
- Patients will not be eligible if they have evidence of active malignancy (other than non-melanoma skin cancer or localized cervical cancer or localised and presumed cured prostatic cancer) within 2 years before randomization and are not receiving specific treatment for these malignancies at baseline assessment;
- Any evidence of severe or uncontrolled systemic diseases, including uncontrolled hypertension and active bleeding diatheses, which in the Investigator's opinion makes it undesirable for the patient to participate in the trial or which would jeopardise compliance with the protocol; or active infection including hepatitis B, hepatitis C and human immunodeficiency virus (HIV). Active infection will include any patients receiving intravenous treatment for infection; active hepatitis B infection will, at a minimum, include all patients who are Hepatitis B surface antigen positive (HbsAg positive) based on serology assessment. Screening for chronic conditions is not required;
- Refractory nausea and vomiting, chronic gastrointestinal diseases, inability to swallow the formulated product, or previous significant bowel resection that would preclude adequate absorption of Osimertinib or Gefitinib;
- Any of the following cardiac criteria:
- Mean resting corrected QT interval (QTc) >470 msec, obtained from 3 ECGs using local clinic ECG machine-derived QTcF value
- Any clinically important abnormalities in rhythm, conduction, or morphology of resting ECG, e.g., complete left bundle branch block, third-degree heart block, second-degree heart block, PR interval >250 msec or history of episodes of bradycardia (<50 BPM);
- Any factors that increase the risk of QTc prolongation or risk of arrhythmic events such as heart failure, hypokalaemia, congenital long QT syndrome family history of long QT syndrome, or unexplained sudden death under 40 years of age in first-degree relatives or any concomitant medication known to prolong the QT interval.
- Abnormal cardiac function: LVEF < 50% (assessed by MUGA or ECHO)
- Past medical history of ILD (Interstitial Lung Disease), drug-induced ILD, radiation pneumonitis which required steroid treatment, or any evidence of clinically active ILD.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Osimertinib till progression
Osimertinib until PD according to RECIST 1.1
|
Osimertinib 60 or 40 mg daily until progression
Other Names:
|
Experimental: Gefitinib till + blood test/progression than Osimertinib
Gefitinib until emergence of positive T790M status ("cfDNA T790M positive progression") followed by Osimertinib until second PD according to RECIST 1.1
|
Osimertinib 60 or 40 mg daily until progression
Other Names:
Gefitinib 250mg daily until progression
Other Names:
|
Active Comparator: Gefitinib till progression than Osimertinib
Gefitinib until PD according to RECIST 1.1 followed by Osimertinib until PD according to RECIST 1.1
|
Osimertinib 60 or 40 mg daily until progression
Other Names:
Gefitinib 250mg daily until progression
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
PFS Rate at 18 months
Time Frame: 24 months after first patient in
|
24 months after first patient in
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
PFS measured from switching to Osimertinib by RECIST criteria 1.1
Time Frame: 24 months after first patient in
|
24 months after first patient in
|
|
Proportion of patients receiving Osimertinib based on the determination of cfDNA T790M mutation positive
Time Frame: 24 months after first patient in
|
24 months after first patient in
|
|
Time to progression on Osimertinib
Time Frame: through study completion
|
through study completion
|
|
Time to symptomatic brain metastases in patients with presence of brain metastases at study entry
Time Frame: 24 months after first patient in
|
24 months after first patient in
|
|
Overall Response Rate (ORR) to Osimertinib
Time Frame: 24 months after first patient in
|
24 months after first patient in
|
|
Treatment duration
Time Frame: 24 months after first patient in
|
24 months after first patient in
|
|
Overall Survival (OS)
Time Frame: 24 months after first patient in
|
24 months after first patient in
|
|
Time to brain progression (TTBP)
Time Frame: 24 months after first patient in
|
24 months after first patient in
|
|
Safety
Time Frame: 24 months after first patient in
|
Number of participants with treatment-related adverse events by CTCAE version 4.0.
Adverse events, serious adverse events and adverse reactions will be monitored.
|
24 months after first patient in
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Rafal Dziadziuszko, MD PhD, Mecical University of Gdansk, Poland
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Respiratory Tract Diseases
- Neoplasms
- Lung Diseases
- Neoplasms by Site
- Respiratory Tract Neoplasms
- Thoracic Neoplasms
- Carcinoma, Bronchogenic
- Bronchial Neoplasms
- Lung Neoplasms
- Carcinoma, Non-Small-Cell Lung
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antineoplastic Agents
- Protein Kinase Inhibitors
- Gefitinib
- Osimertinib
Other Study ID Numbers
- EORTC-1613
- ESR-15-11406 (Other Identifier: Astra Zeneca)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on NSCLC
-
Shanghai Henlius BiotechCompleted
-
The Netherlands Cancer InstituteEnrolling by invitation
-
Centre Oscar LambretUniversity Hospital, LilleTerminated
-
Suzhou Zelgen Biopharmaceuticals Co.,LtdCompleted
-
Bio-Thera SolutionsCompleted
-
Jiangsu Province Nanjing Brain HospitalRecruiting
-
TYK Medicines, IncRecruiting
-
Radboud University Medical CenterPfizer; ImaginAb, Inc.; University Hospital TuebingenNot yet recruitingNSCLCGermany, Netherlands
-
Beta Pharma, Inc.Completed
Clinical Trials on Osimertinib
-
Li ZhangHubei Cancer HospitalNot yet recruitingStage IV Non-small Cell Lung CancerChina
-
AstraZenecaActive, not recruitingNon Small Cell Lung Cancer (Stage III)United States, Spain, Taiwan, Thailand, Vietnam, Turkey, Korea, Republic of, Brazil, Hungary, India, Japan, Mexico, Peru, Russian Federation, China, Malaysia, Argentina
-
Qingdao Central HospitalRecruiting
-
Wuhan Union Hospital, ChinaNot yet recruitingNon Small Cell Lung Cancer
-
Vestre Viken Hospital TrustActive, not recruitingLung CancerDenmark, Sweden, Lithuania, Norway
-
AstraZenecaTerminated
-
Istituto Oncologico Veneto IRCCSActive, not recruitingEGF-R Positive Non-Small Cell Lung CancerItaly
-
Suzhou Genhouse Bio Co., Ltd.RecruitingNon-Small Cell Lung Cancer With EGFR MutationChina
-
Shanghai JMT-Bio Inc.CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Not yet recruitingLocally Advanced or Metastatic Non-Small Cell Lung Cancer | EGFR Exon20 Insertion Mutations
-
Qingdao Central HospitalRecruiting